The Drug Controller General of India (DCGI) has proposed to the Health Ministry to ban Rosiglitazone, an anti-diabetes drug widely used in India for correcting blood sugar levels.

Earlier this month, DCGI Surinder Singh had directed state drug controllers to suspend all licenses for sale and distribution of Rosiglitazone.